LLLilian Yan Liang

Lilian Yan Liang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lilian Yan Liang has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • HBsAg seroclearance further reduces hepatocellular carcinoma but not hepatic decompensation in patients with cirrhosis and complete viral suppression

    by Vicki Wing-Ki Hui, Jasmine Cheuk-Man Tang, Vincent Wai-Sun Wong, Lilian Yan Liang, Yee-Kit Tse, Henry Lik-Yuen Chan, Grace Lai-Hung Wong, Jimmy Che-To Lai, Terry Cheuk-Fung Yip

    Background and Aims: Whether HBsAg seroclearance provides further clinical benefit over complete viral suppression in nucleos(t)ide analogue (NA)-treated patients with chronic hepatitis B with cirrhosis remained unclear. We aimed to compare the risk of HCC and hepatic decompensation in treated patients with cirrhosis with complete viral suppression versus HBsAg seroclearance. Approach and Results: All adult patients with chronic hepatitis B and cirrhosis receiving entecavir/tenofovir between January 2005 and September 2020 were identified. Patients with HCC before or within the first 6 months of baseline, other cancers or liver transplantation before baseline, liver transplantation before HBsAg loss, and without complete viral suppression were excluded. One-year landmark analyses were performed; patients with clinical outcomes or follow-up p =0.030) but not hepatic events (adjusted subdistribution HR: 1.01, 95% CI: 0.52–1.95) than complete viral suppression. Similar results on HCC were observed in a 2-year landmark analysis (adjusted subdistribution HR: 0.37 [0.14–1.04]). Conclusions: HBsAg seroclearance is associated with a lower risk of HCC but not first/further hepatic decompensation in NA-treated patients with chronic hepatitis B and cirrhosis with complete viral suppression.

  • Open Access

    Dynamic Changes in ELF Score Predict Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Antiviral Treatment

    by Lilian Yan Liang, Terry Cheuk‐Fung Yip, Jimmy Che‐To Lai, Amy Shuk‐Man Lam, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong

    Enhanced liver fibrosis (ELF) score is a noninvasive assessment for liver fibrosis. We aimed to evaluate the performance of changes in ELF score 3 years apart in combination with liver stiffness measurement (LSM)‐hepatocellular carcinoma (HCC) score to predict HCC in chronic hepatitis B (CHB) patients. This is a prospective cohort study. Patients who underwent transient elastography (TE) examinations and at intermediate or high risk of HCC defined by LSM‐HCC score were invited to repeat the examination about 3 years later. Their serum samples at these two time points were retrieved to assess the ELF score changes. The primary endpoint was HCC. There were 445 CHB patients (males: 73.9%; mean age: 51.6 ± 10.3 years) who received two TE examinations and ELF scores. Among them, 252 (56.6%) and 193 (43.4%) patients were at intermediate and high HCC risk at first assessment defined by LSM‐HCC score, respectively. Kaplan–Meier analysis showed that the changes in ELF score could stratify the HCC risk in both intermediate‐ and high‐risk patients defined by LSM‐HCC score (p < 0.001 for intermediate‐risk group; p = 0.011 for high‐risk group). Patients remained having mild or moderate fibrosis at both assessments had the lowest risk of HCC (4.0%), followed by patients with fibrosis regressed (11.3%; p = 0.014) during a mean follow‐up of 163 months. Patients remained having or progressed to severe fibrosis were at highest risk of HCC (> 20%). Consistent findings were demonstrated in patients at both intermediate and high risk of HCC defined by LSM‐HCC score. Dynamic changes in ELF score provided additional value to LSM‐HCC score for stratifying HCC risk in CHB patients.


  • Open Access

    Performance of continuous controlled attenuation parameter and liver stiffness measurement by the novel SmartExam in metabolic dysfunction‐associated steatotic liver disease

    by Sherlot J. Song, Asako Nogami, Lilian Y. Liang, Masato Yoneda, Howard H.W. Leung, Atsushi Nakajima, Jimmy C.T. Lai, Grace L.H. Wong, Sally S.T. Shu, Vincent W.S. Wong, et al.

    Background & Aims: FibroScan® Expert 630 and FibroScan® Mini+430 are novel vibration‐controlled transient elastography devices equipped with the same SmartExam software, which allows continuous measurement of controlled attenuation parameter (CAP) during the entire examination. This study aims to compare the CAP variabilities and the quantification for liver fibrosis and steatosis between the conventional FibroScan and the SmartExam‐equipped machines in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD).Methods: This retrospective study included 118 patients with biopsy‐proven MASLD who underwent liver biopsy at two tertiary centres between 2021 and 2023. Liver stiffness and steatosis measurements were performed using both FibroScan machines and M and XL probes for each individual. Liver histology was used as the reference standard for liver fibrosis and steatosis staging.Results: Standard deviations of continuous CAP (cCAP) were significantly lower than those of CAP for all probes (p < .0001). CAP variability was significantly associated with body mass index (p < .01), probe selection (p < .001) as well as the random effect of centre. Only the effect of probe selection (p < .001) was significantly associated with cCAP variability. No significant difference was found in the performance of staging liver fibrosis and steatosis between two types of machines at the same cut‐offs.Conclusions: The SmartExam‐based VCTE reduces the variability of CAP measurement and achieves a similar accuracy as the FibroScan 502 device for the estimation of both hepatic steatosis and fibrosis. Future studies should determine if cCAP is a better tool to monitor changes in steatosis than the original CAP.


  • Open Access

    Diagnostic and prognostic performance of the SAFE score in non‐alcoholic fatty liver disease

    by Guanlin Li, Huapeng Lin, Pimsiri Sripongpun, Lilian Y. Liang, Xinrong Zhang, Vincent W.S. Wong, Grace L.H. Wong, W. Ray Kim, Terry C.F. Yip

    Background & Aims: The steatosis‐associated fibrosis estimator (SAFE) score was developed to detect clinically significant liver fibrosis in patients with NAFLD in the United States. We compare the performance of the SAFE score and other non‐invasive tests to diagnose liver fibrosis and to correlate the scores with liver‐related outcomes in patients with NAFLD in Hong Kong.Methods: This was a retrospective cohort study involving two data sets. The first cohort was a biopsy cohort of NAFLD patients (n = 279), and the second was a territory‐wide cohort of NAFLD patients (n = 4603) retrieved from a territory‐wide electronic healthcare database in Hong Kong.Results: In detecting significant fibrosis, liver stiffness measured by transient elastography had the highest area under the receiver operating characteristic curve (AUROC) (.844), followed by SAFE score (.773). SAFE score had the highest AUROC among blood‐based algorithms (.773 vs. .746 for FIB‐4, .697 for APRI). Based on cut‐off values of SAFE score (0 and 100 points), 854 (18.6%), 1596 (34.6%) and 2153 (46.8%) were in the low‐, intermediate‐ and high‐risk groups, respectively, in the territory‐wide cohort. Six (.7%), 15 (.9%) and 59 (2.7%) developed liver‐related events in those three groups respectively. Among patients who had liver‐related events at 5 years, using the high cut‐off, SAFE score could predict 84.9% of patients accurately, compared to 40.9% for FIB‐4 and 27.2% for APRI.Conclusion: The SAFE score performed well and better than other blood‐based markers in diagnosing significant fibrosis and predicting liver‐related events in Asian patients with NAFLD.


  • Open Access

    Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis

    by Huapeng Lin, Jimmy Che‐To Lai, Grace Lai‐Hung Wong, Adèle Delamarre, Sang Hoon Ahn, Guanlin Li, Beom Kyung Kim, Lilian Yan Liang, Hye Won Lee, Sherlot Juan Song, et al.

    Summary: Background: Baveno VII was proposed for non‐invasive identification of clinically significant portal hypertension. However, a substantial proportion of patients is classified in the grey zone (i.e., liver stiffness 15–24.9 kPa and/or platelet count 9/L).Aims: To evaluate the risk and predictors of hepatic decompensation in patients in the grey zone, and to determine the prognostic role of spleen stiffness measurement.Methods: We included prospective cohorts (from Hong Kong, Korea and France) of patients who had undergone transient elastography examination for chronic liver disease. We estimated risk of hepatic decompensation using competing risk regression with hepatocellular carcinoma and non‐liver‐related death as competing events.Results: We identified 2763 patients with compensated advanced chronic liver disease (cACLD). There were 1243 (44.9%) and 536 (19.4%) patients in the Baveno VII grey zone and high‐risk groups, respectively. The cumulative incidence of decompensation at 5 years was significantly different among low‐risk (0.6% [95% CI: 0.2%–1.3%]), grey zone 4.2% (95% CI: 3.1%–5.4%) and high‐risk groups (11.4% [95% CI: 8.7%–14.6%]). By competing risk analysis, aetiology of liver disease (alcohol‐related liver disease), albumin–bilirubin score and alkaline phosphatase level were independently associated with decompensation among patients in the grey zone. The combination of Baveno VII and spleen stiffness significantly reduced patients classified into grey zone (12.8% in cACLD patients), while maintaining high discrimination of decompensation in low‐ and high‐risk groups.Conclusions: Patients in grey zone of Baveno VII criteria remain at high risk of hepatic decompensation. Clinical risk factors and spleen stiffness can further stratify the risk in such patients.


  • Open Access

    Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial

    by Xinrong Zhang, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Wei-Xuan Leow, Lilian Yan Liang, Lee-Ling Lim, Guanlin Li, Luqman Ibrahim, Huapeng Lin, Jimmy Che To Lai, et al.

    Objective We aimed to test the hypothesis that automated fibrosis score calculation and electronic reminder messages could increase the detection of advanced liver disease in patients with type 2 diabetes. Design In this pragmatic randomised controlled trial at five general medical or diabetes clinics in Hong Kong and Malaysia, we randomly assigned patients in a 1:1 ratio to the intervention group with Fibrosis-4 index and aspartate aminotransferase-to-platelet ratio index automatically calculated based on routine blood tests, followed by electronic reminder messages to alert clinicians of abnormal results, or the control group with usual care. The primary outcome was the proportion of patients with increased fibrosis scores who received appropriate care (referred for hepatology care or specific fibrosis assessment) within 1 year. Results Between May 2020 and Oct 2021, 1379 patients were screened, of whom 533 and 528 were assigned to the intervention and control groups, respectively. A total of 55 out of 165 (33.3%) patients with increased fibrosis scores in the intervention group received appropriate care, compared with 4 of 131 (3.1%) patients in the control group (difference 30.2% (95% CI 22.4% to 38%); pConclusion Automated fibrosis score calculation and electronic reminders can increase referral of patients with type 2 diabetes and abnormal fibrosis scores at non-hepatology settings. Trial registration number NCT04241575.


  • Open Access

    Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study

    by Xinrong Zhang, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Guanlin Li, Huapeng Lin, Lilian Yan Liang, Jimmy Che‐To Lai, Mandy Sze‐Man Lai, Johnny T. K. Cheung, et al.

    Summary: Background & Aims: We aimed to determine the trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D) in 2000–2020.Methods: We conducted a territory‐wide cohort study of adult patients with NAFLD and T2D diagnosed between 1 January 2000 and 31 July 2021 in Hong Kong. T2D was defined by use of any anti‐diabetic agents, laboratory tests and/or diagnosis codes.Results: This study included 16,084 patients with NAFLD and T2D (mean age, 54.8 ± 12.0 years; 7124 male [44.3%]). The percentage of patients achieving individualised haemoglobin A1c (HbA1c) targets increased from 44.5% (95% confidence interval [CI], 42.9–46.1) to 64.8% (95% CI, 64.1–65.5), and percentage of patients achieving individualised low‐density lipoprotein‐cholesterol (LDL‐C) targets increased from 23.3% (95% CI, 21.9–24.7) to 54.3% (95% CI, 53.5–55.1) from 2000–2005 to 2016–2020, whereas percentage of patients achieving blood pressure control (1c targets than non‐cirrhotics. Metformin and statins were underused in cirrhotic patients. Younger patients (18–44 years) were less likely to achieve individualised HbA1c targets than middle‐aged (45–64 years) and older ones (≥65 years).Conclusions: From 2000 to 2020, glycaemic and lipid control improved significantly, whereas blood pressure control remained static among patients with NAFLD and T2D.


  • Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma

    by Grace Lai‐Hung Wong, Vicki Wing‐Ki Hui, Terry Cheuk‐Fung Yip, Lilian Yan Liang, Xinrong Zhang, Yee‐Kit Tse, Jimmy Che‐To Lai, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong

    Summary: Background: Universal vaccination of newborns with hepatitis B virus (HBV) vaccine is the most important strategy to prevent chronic HBV infection and its complications of which hepatocellular carcinoma (HCC) as the deadliest.Aims: To evaluate the impact of universal HBV vaccination on the prevalence of chronic HBV infection, and the incidences of HCC and hepatic events in young adults born before and after the introduction of the universal HBV vaccination programme in 1988 in Hong KongMethods: This was a territory‐wide retrospective observational cohort study of consecutive adult subjects born in 1970–2002 with hepatitis B surface antigen (HBsAg) checked. Subjects born during the vaccination era (1988–2002) were included in the vaccinated cohort; subjects born between 1970 and 1987 were included in the unvaccinated cohort.Results: We included 695,925 subjects for HBV prevalence analysis. Chronic HBV infection dropped from 14.3% in subjects born in 1970, to 6.7% in subjects born in 1988. In total, 53,960 vaccinated and 318,290 unvaccinated subjects who had available clinical data were included for event analysis. HCC and hepatic events occurred in 44 (0.1%) and 75 (0.1%) of the vaccinated subjects and in 1305 (0.4%) and 1806 (0.6%) of the unvaccinated subjects, respectively. All incidence rates remained numerically lower in vaccinated subjects after adjustment for age, gender and antiviral treatment, but failed to reach statistical significance due to very low incidence rates.Conclusions: Universal HBV vaccination markedly reduces the prevalence of chronic HBV infection and may contribute to the decreased incidences of HCC and hepatic events.


  • Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate

    by Lilian Yan Liang, Terry Cheuk‐Fung Yip, Jimmy Che‐To Lai, Amy Shuk‐Man Lam, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong

    Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir for the treatment of chronic hepatitis B (CHB) infection. We aimed to evaluate the impact of switching to TAF on alanine aminotransferase (ALT) normalization and renal safety. We also described the indications of switching to TAF. Consecutive adult CHB patients switched from tenofovir disoproxil fumarate (TDF) dominant therapy to TAF for more than 12 months were identified retrospectively. A subgroup of patients newly switched to TAF was prospectively invited to perform transient elastography examination and dual‐energy X‐ray absorptiometry. The time of switching to TAF was defined as baseline. Among 393 patients in the retrospective cohort, the median ALT at month 12 was significantly lower (21.0 [16.0–29.9] U/L vs. 25.0 [19.0–34.0] U/L; p < 0.001) and ALT normalization rate was higher (89.9% vs. 83.7%; p = 0.037) than those at baseline. Estimated glomerular filtration rate decreased from 12 months before baseline and then increased from baseline to month 12 significantly (69.7 ± 22.0 ml/min/1.73 m2 vs. 68.5 ± 21.5 ml/min/1.73 m2 vs. 69.2 ± 21.5 ml/min/1.73 m2, p = 0.002 (−12 m vs. baseline), p = 0.004 (baseline vs. 12 m)). In the prospective cohort, 103 patients switched to TAF because of age > 60 years (63.1%), bone diseases (54.4%), and renal alteration (42.7%). TAF is associated with ALT improvement and better renal safety than TDF dominant therapy in CHB patients. Most CHB patients switched to TAF because of advanced age, followed by bone disease and renal alteration.


  • Open Access

    Sodium‐glucose co‐transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B

    by Lilian Yan Liang, Vincent Wai‐Sun Wong, Vicki Wing‐Ki Hui, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Grace Chung‐Yan Lui, Henry Lik‐Yuen Chan, Grace Lai‐Hung Wong

    Background Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a novel class of anti-diabetic drugs that lower the blood glucose level by inhibiting the renal glucose reabsorption. We aimed to evaluate the effect of SGLT2i on the risk of hepatic events in diabetic patients with chronic hepatitis B (CHB). Methods This is a retrospective territory-wide cohort study. Nucleos(t)ide analogue (NA)-treated diabetic patients with CHB were included. Patients who used SGLT2i for more than 90 days were classified as SGLT2i users and those who had never used SGLT2i were defined as non-SGLT2i users. The primary endpoint was the cumulative incidence of hepatic events. Results Among 5,276 NA-treated diabetic patients with CHB, 393 (7.4%) patients were SGLT2i users and 4,883 (92.6%) patients were non-users. Ten (2.5%) SGLT2i users and 739 (15.1%) non-users developed hepatic events during the mean follow-up of 25 and 63 months respectively. SGLT2i treatment was significantly associated with a lower risk of hepatic events in univariate analysis (subdistribution hazard ratio (SHR): 0.43, 95% CI: 0.22–0.84, P = 0.013) and log-rank test (P = 0.01) before propensity score (PS) weighting. This association was also observed in Fine-Gray subdistribution hazard regression after PS weighting (weighted SHR: 0.42, 95% CI: 0.19–0.90, P = 0.026). Conclusions Use of SGLT2i may be linked with a lower risk of hepatic events in NA-treated diabetic patients with CHB. Larger cohort studies or randomized trials are warranted.